Skip to main content
Zepbound is the United States brand name for tirzepatide and holds no EU marketing authorisation — the European Medicines Agency has no assessment report under this name. In the European Union the same active substance is sold as Mounjaro.

​
What is Zepbound?

Tirzepatide is given as a once-weekly injection under the skin. It acts on two natural gut-hormone signals at once, GLP-1 and GIP, which together lower appetite and slow how fast food leaves the stomach, so people usually eat less. In the United States, Zepbound is labelled by Eli Lilly and Company for weight reduction and for moderate to severe obstructive sleep apnoea in adults with obesity.
Form: pre-filled injection pen. Frequency: once a week. Status: prescription only.
Zepbound has no EU marketing authorisation for this use. No doctor in the EU can prescribe it for this use — including ours. It may be authorised in another country, or for a different condition.

​
Not marketed in the EU

In the EU, the same active substance is sold as Mounjaro. Tirzepatide was first authorised in September 2022 for type 2 diabetes, and its licence was extended on 11 December 2023 to cover weight management alongside a reduced-calorie diet and more physical activity.

​
How it works

It switches on two gut-hormone receptors at the same time, GIP and GLP-1, which together reduce appetite and slow how quickly the stomach empties.

​
What the studies reported

Figures are the treatment-regimen estimand at week 72 from SURMOUNT-1. People with type 2 diabetes were excluded, everyone also received diet and exercise counselling, and the trial did not follow weight after treatment stopped. Every NCT identifier links to its ClinicalTrials.gov record; a readout is not the same as peer-reviewed publication.
  • ClinicalTrials.gov · NCT04184622 (SURMOUNT-1)

​
What has been reported

Acute pancreatitis was independently confirmed in 3 people on tirzepatide and 1 on placebo across the SURMOUNT-1 safety dataset reviewed by the EMA.

​
What SURMOUNT-1 did not measure

SURMOUNT-1 did not follow weight after treatment stopped, so it provides no data on what happens when tirzepatide is discontinued. People with type 2 diabetes were excluded from the trial, meaning the side-effect profile in that group is drawn from a different dataset. All participants also received diet and exercise counselling, so the figures reflect the medicine alongside lifestyle support, not the medicine alone.

​
Common questions

No. Zepbound has no EU marketing authorisation, so no doctor in the EU can prescribe it for this use. The same active substance, tirzepatide, is sold in the EU under the brand name Mounjaro, which was first authorised for type 2 diabetes in September 2022 and extended to weight management on 11 December 2023.
Zepbound and Mounjaro contain exactly the same active substance — tirzepatide — at the same doses. Zepbound is the US brand name; Mounjaro is the EU brand name. The dosing schedule, side-effect profile and clinical trial data (SURMOUNT-1) are the same.
SURMOUNT-1 did not follow weight after treatment stopped. As with other GLP-1-based medicines, appetite and stomach emptying return to normal once the medicine leaves the body, and weight that was lost may be regained.
No. Tirzepatide acts on two receptors (GIP and GLP-1), while semaglutide acts only on GLP-1. Both are once-weekly injections, but they are different molecules with different trial programmes and different authorised doses.
In SURMOUNT-1, alopecia was reported by 5.1% (5 mg), 4.9% (10 mg) and 5.7% (15 mg) of participants versus 0.9% on placebo. The mechanism is not fully understood, but it is listed in the trial safety data.

​
A step-wise, supervised escalation (as used for tirzepatide in the EU)

1

Weeks 1–4

2.5 mg starting dose, once weekly.
2

From week 5

Step up every 4 weeks as tolerated: 5 → 7.5 → 10 → 12.5 mg.
3

Month 4+

Personalised maintenance dose, up to a maximum of 15 mg per week.
4

Ongoing

Quarterly medical reviews.
Once-weekly self-injection is given in the thigh, abdomen or upper arm, and is combined with diet and physical activity — tirzepatide complements, not replaces, lifestyle change.

​
Who it is not suitable for

  • Personal or family history of medullary thyroid carcinoma or MEN 2
  • Pregnancy, planned pregnancy in the next 2 months, or breastfeeding
  • History of pancreatitis
  • Type 1 diabetes or diabetic ketoacidosis
  • Severe gastroparesis
You pay for any medication separately at the pharmacy you choose. Hi-Doctor does not sell medications.

​
How Hi-Doctor handles it

Weight-loss treatment runs as an ongoing plan: first consultation included, then renewals reviewed by your doctor as part of ongoing care. See the weight management programme for how the categories work, and pricing for how the plan is billed. Related: Qsymia, another US weight-loss medicine without EU-wide authorisation. For the EU-authorised version of tirzepatide, see Mounjaro. For other weight-management options, see semaglutide (Wegovy) and the full treatment areas Hi-Doctor covers.

​
Start a consultation

Weight-loss consultation

Answer the weight-loss questionnaire and a registered doctor reviews it. They decide whether treatment is appropriate, which one, and at what dose — and declining is a normal outcome. See what it costs and how the review works.
This page is reference information, not medical advice and not a prescription. Whether a medicine is appropriate for you is decided by a registered doctor after reviewing your consultation.